Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The project is a multi-center, prospective cohort study. The study's total targeted enrollment is 400 first-episode patients with major depressive disorder (MDD) and 400 healthy controls.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking University
• Treatments: Antidepressive Agents; Citalopram; Dexetimide; Duloxetine Hydrochloride; Lithium Carbonate; Mirtazapine

Criteria

Inclusion Criteria:

1. Patients with depression

• The inclusion criteria for depressed patients were: male or female outpatients aged between 18 and 55 years old

• Currently in acute depressive episode

• Total HAMD-17 score≥14 at baseline visit.

• The diagnosis of depression was confirmed by a trained psychiatrists using the Mini-International Neuropsychiatric Interview (MINI).

• The patients participating in imaging scans should additionally satisfy: not taking psychiatric drugs within last two weeks (except for benzodiazepine) or fluoxetine last one month

• Not receiving ECT within last 6 months.

Exclusion Criteria:

• Unable to complete the questionnaire and psychological assessment independently

• Significant cognitive impairments determined by system mental examination and inability to sign an informed consent form

• Past or presently suffering from other psychiatric disorders, alcohol and drug dependence

• Suffering from major physical diseases, such as cardiovascular and cerebrovascular diseases, respiratory diseases, kidney disease, cancer and so on; personality disorder

• Intellectual disabilities

• Suicidal behavior

• Being participating in other studies.